Oral Vitamin K—US Newborns Need an FDA-Approved Option

This Viewpoint describes rising rates of parent declination of intramuscular vitamin K prophylaxis for newborns and recommends development of a US Food and Drug Administration (FDA)–approved oral formulation.

Corresponding Author: Laura R. Kair, MD, MAS, University of California Davis Health, 2516 Stockton Blvd, Ticon II, Sacramento, CA 95817 (lrkair@health.ucdavis.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.